UGT1A9

UDP-glucuronosyltransferase 1A9 · O60656 · UGT1A9 on Sugi Atlas →

1,949 patent compounds predicted against UGT1A9, 1,610 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
Diclofenac (SCHEMBL2799)	1.00	1/20
Diclofenac (SCHEMBL996716)	1.00	1/20
Diclofenac (SCHEMBL24010)	0.97	1/20
Diclofenac (SCHEMBL40785)	0.97	1/20
Diclofenac (SCHEMBL418230)	0.97	1/20
Diclofenac (SCHEMBL1178502)	0.97	1/20
Diclofenac (SCHEMBL1231246)	0.97	1/20
Diclofenac (SCHEMBL1651599)	0.97	1/20
Diclofenac (SCHEMBL2216520)	0.97	1/20
Diclofenac (SCHEMBL3176618)	0.97	1/20
Diclofenac (SCHEMBL3184302)	0.97	1/20
Diclofenac (SCHEMBL3466580)	0.97	1/20
Diclofenac (SCHEMBL4614418)	0.97	1/20
Diclofenac (SCHEMBL4615491)	0.97	1/20
Diclofenac (SCHEMBL6509236)	0.94	1/20
Diclofenac (SCHEMBL6765357)	0.91	1/20
Diclofenac (SCHEMBL4566078)	0.89	1/20
Diclofenac (SCHEMBL7776173)	0.89	1/20
Diclofenac (SCHEMBL2899504)	0.86	1/20
Diclofenac (SCHEMBL691812)	0.84	1/20

Clinical trials — most relevant to UGT1A9 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Clinical Trial Assessing Once Daily Raltegravir Administration (800 mg QD) in HIV-1-Infected Patients Receiving Unboosted Atazanavir (400 mg QD)- Based Antiretroviral Therapy	PHASE4	COMPLETED
Cholestatic Drug-induced Liver Injury	PHASE4	UNKNOWN
Effect of Genetic Polymorphisms of UGT on the PKs of Indapamide in Egyptians	PHASE4	UNKNOWN
CBD for Pain Following Orthopedic Shoulder Surgery	PHASE1/PHASE2	RECRUITING
Evaluation of Treatment Response With CHOI and RECIST Criteria and CT Texture Analysis in Patients With Metastatic Colorectal Cancer Treated With Regorafenib	PHASE2	COMPLETED
Irinotecan and Docetaxel in Treating Patients With Metastatic or Locally Recurrent Head and Neck Cancer	PHASE2	COMPLETED
Oral Cannabidiol for Opioid Withdrawal	PHASE1/PHASE2	COMPLETED
Green Tea Extract in Treating Patients With Nonmetastatic Bladder Cancer	PHASE2	COMPLETED
Irinotecan, Oxaliplatin, and Capecitabine as First-Line Therapy in Treating Patients With Metastatic or Unresectable Locally Advanced Small Bowel Cancer	PHASE2	COMPLETED
Genotype-Directed Study Of Irinotecan Dosing In FOLFIRI + BevacizumabTreated Metastatic Colorectal Cancer	PHASE2	COMPLETED
Safety Study of ON 01910.Na in Combination With Irinotecan or Oxaliplatin	PHASE1	COMPLETED
Phase I Study of BL0020, a Novel Anti-tumor Drug, in Adult Subjects With Advanced Solid Tumors	PHASE1	UNKNOWN
Pharmacokinetics of Mycophenolate Mofetil in Healthy Volunteers	PHASE1	COMPLETED
Cotinine Metabolism in Infants and Children	PHASE1	COMPLETED
Veliparib and Irinotecan Hydrochloride in Treating Patients With Cancer That Is Metastatic or Cannot Be Removed by Surgery	PHASE1	COMPLETED
A Phase I Study to Assess the Safety and Tolerability of BL0006 for Patients With Advanced Solid Tumours	PHASE1	UNKNOWN
Study of NK012 in Patients With Refractory Solid Tumors	PHASE1	COMPLETED
Temozolomide, Vincristine, and Irinotecan in Treating Young Patients With Refractory Solid Tumors	PHASE1	COMPLETED
Phase I Study of Weekly Topotecan in Combination With Sorafenib in Treatment of Relapsed Small Cell Lung Cancer	PHASE1	COMPLETED
Safety Study of IHL-305 (Irinotecan Liposome Injection) to Treat Advanced Solid Tumors	PHASE1	COMPLETED
A Study to Assess Effects of Clarithromycin on Pharmacokinetics of JNJ-54861911 in Healthy Male Participants	PHASE1	COMPLETED
Irinotecan in Treating Asian Patients With Solid Tumors	PHASE1	COMPLETED
Contribution of UGT2B17 to the Pharmacokinetics of Diclofenac	EARLY_PHASE1	RECRUITING
Development of PK/PD Model for Individualized Propofol Dosing	nan	COMPLETED
Exploration of the Dynamic Changes and Mechanisms of the Immune Microenvironment in Advanced Colorectal Cancer Treated With IBI363 Combination Therapy	nan	RECRUITING
Genetic Study of Patients Previously Treated With Flavopiridol on Clinical Trial NCI-97-C-0171C	nan	COMPLETED
Escalated Dose of Irinotecan in mCRC	nan	COMPLETED
Evaluating a Pharmacogenetic Testing Panel in Patients Suspected to be at Increased Risk for Pharmacogenetics-related AEs While Receiving Fluoropyrimidine or Irinotecan Therapy	nan	COMPLETED
Genetic Trial to Study Diarrhea in Patients With Stage III Colon Cancer Who Are Receiving Chemotherapy	nan	COMPLETED
Evaluating the Safety and Pharmacokinetics of Raltegravir in Infants	nan	COMPLETED

Related proteins — ESM-2 sequence neighbours (a UGT1A9 binder may also engage these)

Protein	Name	Similarity
UGT1A8	UDP-glucuronosyltransferase 1A8	1.000	landscape →
UGT1A7	UDP-glucuronosyltransferase 1A7	1.000	landscape →
UGT1A10	UDP-glucuronosyltransferase 1A10	1.000	landscape →
Q64633	—	0.996	Q64633 →
Q62452	—	0.989	Q62452 →
Q6ZQM8	—	0.987	Q6ZQM8 →
Q64634	—	0.969	Q64634 →
UGT1A1	UDP-glucuronosyltransferase 1A1	0.950	landscape →
UGT1A3	UDP-glucuronosyltransferase 1A3	0.947	landscape →
UGT1A4	UDP-glucuronosyltransferase 1A4	0.942	landscape →
P35504	—	0.940	P35504 →
UGT1A6	UDP-glucuronosyltransferase 1A6	0.935	landscape →
Q63886	—	0.934	Q63886 →
Q4R766	—	0.933	Q4R766 →
Q64638	—	0.932	Q64638 →
Q6AYT7	—	0.931	Q6AYT7 →
B2GV54	—	0.930	B2GV54 →
Q99LR1	—	0.929	Q99LR1 →
P20720	—	0.929	P20720 →
Q64550	—	0.928	Q64550 →
B4F753	—	0.928	B4F753 →
Q28612	—	0.927	Q28612 →
Q9EQW8	—	0.926	Q9EQW8 →
Q64637	—	0.926	Q64637 →
Q64435	—	0.925	Q64435 →
O95803	—	0.925	O95803 →
Q08DW9	—	0.924	Q08DW9 →
ABHD12	Lysophosphatidylserine lipase ABHD12	0.924	landscape →
Q9EQH7	—	0.922	Q9EQH7 →
P08430	—	0.922	P08430 →